Biotechnology

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

A novel vaccine protects shrimp by immunizing their parents, offering a solution to devastating outbreaks and a path to sustainable global protein production.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.

A new partnership aims to tackle the growing global health crisis of invasive fungal infections, a silent killer claiming millions of lives annually.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

Pimicotinib, a once-daily pill for tenosynovial giant cell tumor, gains FDA review, offering new hope for patients beyond invasive surgery.

Cosmetics brand Sorevna is diving into the crowded bath and body sector, promising a revolutionary launch. But can its science-first approach succeed?

The deal completes insitro’s TherML platform, integrating physics-informed AI to design better drugs faster by solving efficacy and manufacturing hurdles at once.

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

LyfeSci's acquisition of Clinically Media aims to fix the clinical trial bottleneck by integrating patient recruitment, promising faster, more diverse studies.

Biotech veteran Kamran Tavangar, who built a multi-billion dollar company at LabCentral, returns to lead its science strategy and shape the future of innovation.

With a new name and a laser focus on its lead hemophilia A drug, Metagenomi Therapeutics signals a major shift from platform tech to clinical powerhouse.

Following a successful three-year transformation, B-FLEXION acquires full ownership of Radius Health, betting big on its blockbuster osteoporosis drug TYMLOS®.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.